Market Cap
Stock Chart
Mesoblast - 30 Day Poll
Recent BLOGS About Mesoblast Add New
Latest Company News
|
New Teva Representative Joins Mesoblast Board of Directors
MarketWatch (press release) - May 10, 2012 MELBOURNE, Australia, May 10, 2012 /PRNewswire via COMTEX/ -- Global regenerative medicine company Mesoblast Limited (asx:MSB) today announced the appointment of Dr Ben-Zion Weiner, Special Adviser to the CEO of Teva Pharmaceutical Industries Ltd, ...
|
|
MESOBLAST LIMITED : MSB ASX NEW DIRECTOR - 10 MAY 2012
4-traders - May 10, 2012 NEW TEVA REPRESENTATIVE JOINS MESOBLAST BOARD OF DIRECTORS Melbourne, Australia; 10 May 2012: Global regenerative medicine company Mesoblast Limited (ASX: MSB) today announced the appointment of Dr Ben-Zion Weiner, Special Adviser to the CEO of Teva ...
Teva Representative Joins Mesoblast's Board of Directors - BiotechStockTrader.com |
|
Australian Stock Market Report – Midday 5/2/2012
International Business Times AU - May 2, 2012 By Vittorio Hernandez | May 2, 2012 1:43 PM EST The Australian share market improved for the second straight day yesterday, with the All Ordinaries Index (XAO) up 30 points to 4497 points.
|
|
Midday: Aus shares reverse gains
Finance News Network - May 2, 2012 Buoyed by positive offshore leads, on the back of strong US and Chinese manufacturing data, the Australian share market rose at open but reversed gains and is trading flat noon.
|
|
Three questions to answer before the market plunges
Yahoo!7 News - Apr 26, 2012 Bruce Jackson is the General Manager of popular investing website The Motley Fool. He has written thousands of articles and has also co-authored the best selling The Motley Fool UK Investment Workbook.
|
|
Mesoblast Ltd Enters Into Strategic Alliance With Lonza Group Ltd
Reuters Key Development - Sep 26, 2011 |
|
Mesoblast Ltd Receives Clearance To Begin First European Trial Of Allogeneic Or 'Off-The-Shelf' Stem Cell Treatment For Heart Attacks
Reuters Key Development - Sep 5, 2011 |
Website
Videos related to Mesoblast
Company Profile
Summary
Mesoblast Limited (Mesoblast) is a biotechnology company committed to the development of adult stem cell products targeting a range of bone, cartilage and musculoskeletal conditions. In late 2010 Mesoblast acquired the rest of Angioblast making the deal to buy Angioblast at $240 million.
Finance
Jan 2012 Mesoblast reported cash reserves of $260M.
Half year revenue of approx. $18.7M
6 month loss for period to Jan 2012 approx. $44.1
Cardiovascular stem cell therapy: The Company is developing out the same platform technology for the treatment of cardiovascular diseases, including repair and regeneration of blood vessels and heart muscle. Mesoblast is developing an allogeneic or off-the-shelf cell product, called NeoFuse, to generate bony spinal fusion.
Revascor, their proprietary "off the shelf" adult stem cell product for heart failure, have continued to show sustained improvement in heart muscle function at six months.
- Major Adverse Cardiac Events (MACE) significantly reduced in MPC‐treated patients over mean 22 month follow‐up (p=0.036). MACE is composite of mortality/heart attacks/revascularization
- MACE risk over time reduced by 78% in MPC‐treated patients vs controls (p=0.011), with 60‐90% risk reduction at every MPC dose
- cardiac mortality significantly reduced in MPC‐treated patients compared with controls overmean 22 month follow‐up (2% vs 20%, p=0.02)
- highest dose of Revascor™ completely prevented any deaths or episodes of heart failure hospitalization over 18 months of follow‐up
- highest dose showed evidence of remodeling (reduction in heart volumes) and improvement in functional capacity (increased walking distance), which are key parameters in congestive heart failure
Based on these results, Teva and Mesoblast are moving forward with Phase 3 trial of high dose Revascor™ in heart failure patients
Allogeneic MPCs For Treatment Of Type 2 Diabetes - anther program with preliminary data
Stem cells for back/disc problems: In August 2009, the United States Food and Drug Administration cleared a Phase II clinical trial of its allogeneic adult stem cells for use in minimally invasive lumbar spinal fusion surgery. The 24-patient trial, based at multiple United States sites, is comparing the effectiveness and safety of two low doses, NeoFuse with autograft in minimally invasive surgery for fusion of the lumbar spine.
Teva strategic alliance
- Teva has exclusive worldwide commercialization rights to selected cardiovascular and neurologic indications, holds 19.99% stake in Mesoblast
- Teva responsible for funding Phase 2b and Phase 3 clinical development
- Mesoblast eligible to receive up to US$1.7 billion in milestone payments, plus revenue split
- Mesoblast retains all manufacturing rights
- Mesoblast cash balance of US$260 million to fund other major indications including
- type 2 diabetes
- inflammatory diseases of various tissues (eg lungs)
- immunologic conditions (eg rheumatoid arthritis)
- ophthalmic indications
- orthopedic cartilage and bone conditions
